Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Amy Feller who wrote (771)	1/7/1999 4:47:00 PM
From: Sun Tzu	Read Replies (2) \| Respond to of 1754

Bad bad girl Amy <G> how have you been? Did you ever come to the Art of Investing thread? Here is what may have caused the rise as a continuation from yesterday: NEW YORK, Jan 6 (Reuters) - Warburg Dillon Read on Wednesday said said analyst Matthew Dodds raised his rating on the shares of Baxter International Inc. (NYSE:BAX - news) to strong buy from hold. -- set a 12-18 month price target of $80 a share, up from $64. -- also raised price target on VISX Inc. (Nasdaq:VISX - news) to $110 from $85. Held rating at strong buy. -- Baxter shares rose 3-13/16 to 66-7/8. -- VISX shares rose 3-1/8 to 91-3/4. ((-- New York newsroom, 212 859-1700)